SIL204 Treatment for KRAS-Driven Tumors Advances to Phase 2/3 Clinical Trials

Research indicates that the SIL204 treatment may help the immune system combat KRAS-driven tumors, with the treatment recently progressing to Phase 2/3 clinical evaluation and beginning its first clinical trial at Tel Aviv Sourasky Medical Center.